A novel K5091 mutation of KIT identified in familial mastocytosis -: in vitro and in vivo responsiveness to imatinib therapy

被引：117

作者：

Zhang, LY

Smith, ML

Schultheis, B

Fitzgibbon, J

Lister, TA

Melo, JV

Cross, NCP

Cavenagh, JD ^{[1
]}

机构：

[1] St Bartholomews Hosp, Dept Haematol, London EC1A 7BE, England

[2] Wessex Reg Genet Lab, Salisbury, Wilts, England

[3] St Bartholomews Hosp, Canc Res UK Med Oncol Unit, London EC1A 7BE, England

[4] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, London, England

[5] Hammersmith Hosp, London, England

来源：

LEUKEMIA RESEARCH | 2006年 / 30卷 / 04期

关键词：

KIT; familial mastocytosis; imatinib; K509I;

D O I：

10.1016/j.leukres.2005.08.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

KIT mutation has been implicated in sporadic mastocytosis, yet clusters in only a few sites in the molecule. For those malignancies associated with KIT mutation or over-expression, imatimb offers a specific therapeutic option, yet it has no effect on D816V mutation commonly seen in sporadic mastocytosis. The majority of cases of familial mastocytosis seem to lack KIT mutation. We report a kindred with mastocytosis in whom in vitro and in vivo sensitivity to imatimb was demonstrated. Mutation analysis of the KIT coding region in this family identified a novel A>T mutation at nucleotide 1547 [K509I] in exon 9 in both of the affected patients. (C) 2005 Elsevier Ltd. All rights reserved.

引用

收藏

页码：373 / 378

页数：6

相关论文

共 26 条

[11] Mastocytosis: recent advances in defining the disease [J].

Hartmann, K ;

Henz, BM .

BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (04) :682-695

[12] Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis [J].

Longley, BJ ;

Metcalfe, DD ;

Tharp, M ;

Wang, XM ;

Tyrrell, L ;

Lu, SZ ;

Heitjan, D ;

Ma, YS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (04) :1609-1614

[13] ACHALASIA DUE TO DIFFUSE ESOPHAGEAL LEIOMYOMATOSIS AND INHERITED AS AN AUTOSOMAL DOMINANT DISORDER - REPORT OF A FAMILY STUDY [J].

MARSHALL, JB ;

DIAZARIAS, AA ;

BOCHNA, GS ;

VOGELE, KA .

GASTROENTEROLOGY, 1990, 98 (05) :1358-1365

[14] Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells [J].

Ning, ZQ ;

Li, J ;

Arceci, RJ .

BLOOD, 2001, 97 (11) :3559-3567

[15] Familial gastrointestinal stromal tumours with germline mutation of the KIT gene [J].

Nishida, T ;

Hirota, S ;

Taniguchi, M ;

Hashimoto, K ;

Isozaki, K ;

Nakamura, H ;

Kanakura, Y ;

Tanaka, T ;

Takabayashi, A ;

Matsuda, H ;

Kitamura, Y .

NATURE GENETICS, 1998, 19 (04) :323-324

[16] FIP1L1-PDGFRA fusion:: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia [J].

Pardanani, A ;

Brockman, SR ;

Paternoster, SF ;

Flynn, HC ;

Ketterling, RP ;

Lasho, TL ;

Ho, CL ;

Li, CY ;

Dewald, GW ;

Tefferi, A .

BLOOD, 2004, 104 (10) :3038-3045

[17] Imatinib for systemic mast-cell disease [J].

Pardanani, A ;

Elliott, M ;

Reeder, T ;

Li, CY ;

Baxter, EJ ;

Cross, NCP ;

Tefferi, A .

LANCET, 2003, 362 (9383) :535-537

[18] Lack of c-kit mutation in familial urticaria pigmentosa [J].

Rosbotham, JL ;

Malik, NM ;

Syrris, P ;

Jeffery, S ;

Bedlow, A ;

Gharraie, S ;

Murday, VA ;

Holden, CA ;

Carter, ND .

BRITISH JOURNAL OF DERMATOLOGY, 1999, 140 (05) :849-852

[19]

Sato-Matsumura KC, 1999, BRIT J DERMATOL, V140, P1130

[20] Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease [J].

Scheijen, B ;

Griffin, JD .

ONCOGENE, 2002, 21 (21) :3314-3333